- Home
- BDSX vs RCAT Comparison
BDSX vs RCAT Comparison
Compare BDSX & RCAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BDSX
- RCAT
- Stock Information
- Founded
- BDSX 2005
- RCAT 2002
- Country
- BDSX United States
- RCAT United States
- Employees
- BDSX N/A
- RCAT N/A
- Industry
- BDSX Precision Instruments
- RCAT Wholesale Distributors
- Sector
- BDSX Health Care
- RCAT Industrials
- Exchange
- BDSX Nasdaq
- RCAT Nasdaq
- Market Cap
- BDSX 115.4M
- RCAT N/A
- IPO Year
- BDSX 2020
- RCAT 2017
- Fundamental
- Price
- BDSX $0.28
- RCAT $7.06
- Analyst Decision
- BDSX Strong Buy
- RCAT Buy
- Analyst Count
- BDSX 5
- RCAT 1
- Target Price
- BDSX $1.75
- RCAT $13.00
- AVG Volume (30 Days)
- BDSX 1.8M
- RCAT 10.5M
- Earning Date
- BDSX 08-06-2025
- RCAT 08-07-2025
- Dividend Yield
- BDSX N/A
- RCAT N/A
- EPS Growth
- BDSX N/A
- RCAT N/A
- EPS
- BDSX N/A
- RCAT N/A
- Revenue
- BDSX $74,463,000.00
- RCAT $2,291,089.00
- Revenue This Year
- BDSX $17.29
- RCAT $1,023.35
- Revenue Next Year
- BDSX $29.33
- RCAT $88.95
- P/E Ratio
- BDSX N/A
- RCAT N/A
- Revenue Growth
- BDSX 35.76
- RCAT N/A
- 52 Week Low
- BDSX $0.17
- RCAT $1.10
- 52 Week High
- BDSX $2.04
- RCAT $15.27
- Technical
- Relative Strength Index (RSI)
- BDSX 42.55
- RCAT 48.44
- Support Level
- BDSX $0.25
- RCAT $6.75
- Resistance Level
- BDSX $0.31
- RCAT $7.54
- Average True Range (ATR)
- BDSX 0.02
- RCAT 0.61
- MACD
- BDSX 0.01
- RCAT -0.13
- Stochastic Oscillator
- BDSX 40.00
- RCAT 15.44
About BDSX Biodesix Inc.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.